-
October 20, 2018Elpiscience Announces Filing of IND for ES101
Shanghai, 2018.11.20. Elpiscience announced today that it has submitted an Investigational New Drug (IND) application to the Center of Drug Evaluation (CDE) in Beijing to support the initiation o...
-
May 01, 2018Elpiscience and Inhibrx Announce an Exclusive Collaboration and License Agreement of INBRX-106 (ES102) in Greater China
Shanghai and San Diego, May 1st 2018. Elpiscience Biopharmaceutical Ltd (Elpiscience) has entered into a licensing agreement with Inhibrx, Inc., pursuant to which Elpiscience was granted an exclu...
-
March 01, 2018Elpiscience and Inhibrx Announce an Exclusive Collaboration and License Agreement of INBRX-105 (ES101) in Greater China
Shanghai and San Diego, March 01st 2018. Elpiscience Biopharmaceutical, Ltd. (Elpiscience), a biotech company focusing on the discovery and development of next-generation cancer immunotherapies, ...
-
October 08, 2017Elpiscience Announces Inauguration in Zhangjiang
Shanghai, October 8, 2017. Elpiscience, a start-up biopharma focusing on cancer immunotherapies, announces that it officially starts the operation in Zhangjiang High-Tech Park. Elpiscience was fo...
-
August 30, 2017Elpiscience Completes Series A Financing of 20 Million USD
Shanghai, August 30, 2017. Elpiscience announces it has raised 20 million USD in series A financing, invested by Lilly Asia Ventures (LAV). Elpiscience intends to use the proceeds from the financ...
-
June 25, 2017Elpiscience Announces the Establishment of Board of Directors
Shanghai, June 25, 2017. Elpiscience has established its board of directors and held the first meeting in Shanghai. Board members include Darren Ji (co-founder, CEO), Hongtao Lu (co-founder, CSO), Dav...